Axsome Therapeutics (AXSM) News Today → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free AXSM Stock Alerts $71.71 +0.19 (+0.27%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performancemarkets.businessinsider.com - April 26 at 11:47 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Expected to Post Q1 2024 Earnings of ($1.26) Per Shareamericanbankingnews.com - April 20 at 1:32 AMBrokers Offer Predictions for Axsome Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:AXSM)marketbeat.com - April 19 at 8:18 AMStrong Buy on Axsome’s Auvelity Amidst Competitive MDD Marketmarkets.businessinsider.com - April 18 at 7:36 AMAuvelity’s Strong Performance Sustains Buy Rating for Axsome Therapeuticsmarkets.businessinsider.com - April 16 at 7:50 AMPhocas Financial Corp. Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - April 15 at 8:29 AMAxsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meetingglobenewswire.com - April 15 at 7:00 AMLeerink Partnrs Research Analysts Reduce Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - April 11 at 7:58 AMAxsome Therapeutics' (AXSM) Overweight Rating Reaffirmed at Cantor Fitzgeraldmarketbeat.com - April 10 at 10:25 AM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AMAxsome Therapeutics to Report First Quarter 2024 Financial Results on May 6globenewswire.com - April 10 at 7:00 AMBuy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potentialmarkets.businessinsider.com - April 2 at 5:58 PMHC Wainwright Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)marketbeat.com - April 2 at 9:12 AMInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 24,662 Shares of Stockinsidertrades.com - April 2 at 4:14 AMInsider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)finance.yahoo.com - April 2 at 3:16 AMAxsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorderglobenewswire.com - April 1 at 7:00 AMVanguard Group Inc. Decreases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - March 29 at 4:19 AMQ2 2024 EPS Estimates for Axsome Therapeutics, Inc. Lowered by HC Wainwright (NASDAQ:AXSM)marketbeat.com - March 28 at 8:43 AMOptimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite Challengesmarkets.businessinsider.com - March 27 at 10:07 AM3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch Listinvestorplace.com - March 27 at 7:44 AMMaintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market Risksmarkets.businessinsider.com - March 26 at 11:16 AMAxsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at Truist Financialmarketbeat.com - March 26 at 9:34 AMAxsome Therapeutics (NASDAQ:AXSM) PT Raised to $190.00marketbeat.com - March 26 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)markets.businessinsider.com - March 26 at 1:15 AMWhat's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?msn.com - March 25 at 3:11 PMAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $80.66marketbeat.com - March 25 at 11:54 AMAxsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patientsglobenewswire.com - March 25 at 7:00 AMAxsome Therapeutics sleep disorder therapy succeeds in late-stage trialreuters.com - March 25 at 6:55 AMAxsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsyglobenewswire.com - March 25 at 6:30 AMBuying These Dirt-Cheap Stocks Could Be a Brilliant Movefinance.yahoo.com - March 23 at 6:54 AMBuying These Dirt-Cheap Stocks Could Be a Brilliant Movefool.com - March 23 at 6:45 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Wellington Management Group LLPmarketbeat.com - March 23 at 4:08 AMAxsome Triumphs Over Major Depressive Disorder With Auvelityfinance.yahoo.com - March 22 at 10:48 AMAxsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 20 at 8:11 AMBaird starts Axsome at outperform, cites upcoming datamsn.com - March 19 at 5:45 PMAxsome Therapeutics, Inc.: Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorderfinanznachrichten.de - March 19 at 12:45 PMBaird starts Axsome Therapeutics stock at Outperform on promising trial outlookinvesting.com - March 19 at 12:45 PMAxsome Therapeutics Gains After Initiation Of Paradigm Phase 3 Trial Of Solriamfetolmarkets.businessinsider.com - March 19 at 12:45 PMAxsome Therapeutics (NASDAQ:AXSM) Research Coverage Started at Robert W. Bairdmarketbeat.com - March 19 at 8:46 AMAxsome Therapeutics’ Auvelity Rebounds: A Buy Rating Reinforced by Prescription Growth and Market Resiliencemarkets.businessinsider.com - March 19 at 7:44 AMAxsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorderglobenewswire.com - March 19 at 7:00 AMAXSM Apr 2024 120.000 callfinance.yahoo.com - March 17 at 1:36 AMAXSM Apr 2024 87.500 putfinance.yahoo.com - March 17 at 1:36 AMAXSM Apr 2024 87.500 callfinance.yahoo.com - March 16 at 3:23 PMAXSM Apr 2024 92.500 putfinance.yahoo.com - March 16 at 3:23 PMAXSM Apr 2024 72.500 callfinance.yahoo.com - March 16 at 10:22 AMAXSM Apr 2024 50.000 putfinance.yahoo.com - March 16 at 10:22 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Roger Jeffs Sells 29,976 Sharesinsidertrades.com - March 16 at 8:16 AMRoger Jeffs Sells 29,976 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stockmarketbeat.com - March 15 at 10:51 PMAxsome Therapeutics (NASDAQ:AXSM) Stock Price Up 6.1%marketbeat.com - March 15 at 3:34 PM Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work? Click Here To Get Your Free Copy AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.540.32▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼16▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BHC News PBH News XENE News FOLD News IDYA News RARE News BHVN News ARWR News HCM News ACAD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
